{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:54:07Z","timestamp":1788609247696,"version":"build-2803163510"},"reference-count":57,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T00:00:00Z","timestamp":1734220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["#75D30121C12574"],"award-info":[{"award-number":["#75D30121C12574"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Opioid overdose rates continue to rise in the United States while access to treatment options remains limited. The X waiver, which allowed clinicians to prescribe buprenorphine, a medication for opioid use disorder (MOUD), in an outpatient setting, was eliminated in December 2022 with hopes of increasing buprenorphine access. We used a quasi-experimental approach to evaluate how eliminating the X waiver affected buprenorphine prescribing in Pennsylvania.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Drawing on Pennsylvania Prescription Drug Monitoring Program data from July 1, 2016, to December 31, 2023, we used a difference-in-differences (DD) approach to assess changes in buprenorphine prescribing between Pennsylvania counties with the proportion of X-waivered providers per county population above the median versus counties with the proportion below the median, before and after the elimination of the X waiver. We also tested whether areas most affected by the opioid epidemic with the highest rates of opioid overdose were more impacted by the X-waiver elimination, using opioid overdose death rates from a pretreatment baseline period (2016-2018) for each county.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirty-one counties were categorized as above the median and 32 as below the median. We did not observe a significant difference in the effects of eliminating the X waiver on buprenorphine dispensation (DD estimate: \u22120.6%, 95% CI: \u22127.5%-6.2%) between above versus below-the-median counties in Pennsylvania. We also did not find a significant effect of the X-waiver elimination on buprenorphine dispensation in counties most affected by the opioid epidemic (difference-in-difference-in-differences estimate 1.6%, 95% CI: \u221210.2%-13.4%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>We found no evidence that eliminating the X waiver had a significant impact on buprenorphine dispensing in Pennsylvania in counties with fewer waivered prescribers or higher fatal overdose rates. Additional efforts to increase buprenorphine use will likely need to address systemic barriers and stigma limiting MOUD access.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342241303583","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T05:42:26Z","timestamp":1735018946000},"page":"503-509","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Examining the Impact of Eliminating the X Waiver on Buprenorphine Dispensation in 63 Counties in Pennsylvania"],"prefix":"10.1177","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6343-1367","authenticated-orcid":false,"given":"Rebecca C.","family":"Bilden","sequence":"first","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8277-0425","authenticated-orcid":false,"given":"Mark S.","family":"Roberts","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-458X","authenticated-orcid":false,"given":"Bradley D.","family":"Stein","sequence":"additional","affiliation":[{"name":"RAND Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-210X","authenticated-orcid":false,"given":"Daniel B.","family":"Jones","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,15]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"WONDER C. Data from: Rate of National Drug Overdose Deaths* Involving Select Prescription and Illicit Drugs. 2023."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7015a1"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108350"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.3591"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-04943-6"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06256-5"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0844562121996222"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12404"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2021.1891492"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2021.03.023"},{"key":"e_1_3_3_12_2","first-page":"3019","article-title":"Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians","volume":"15","author":"DeFlavio JR","year":"2015","unstructured":"DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15:3019.","journal-title":"Rural Remote Health"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1377-y"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1037\/a0022776"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/jnu.12871"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108729"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7832752"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2020.1787299"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.14733"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4469"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.13113"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.05.004"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2757"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.04.005"},{"key":"e_1_3_3_25_2","unstructured":"FAQs About the Final Rule Raising the Buprenorphine Patient Limit. American Society of Addiction Medicine. Accessed March 25 2024. https:\/\/www.asam.org\/docs\/default-source\/advocacy\/faq-on-how-to-navigate-the-final-rule.pdf?sfvrsn=9af77c2_0"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2015.302664"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.25999"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.14045"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2312906"},{"key":"e_1_3_3_30_2","unstructured":"Data from: Area Health Resources Files. 2023."},{"key":"e_1_3_3_31_2","unstructured":"IVP-20: opioid overdose death rate. PA Department of Health. 2024. Accessed June 20 2024. https:\/\/www.health.pa.gov\/topics\/HealthStatistics\/HealthyPeople\/Documents\/current\/county\/ivp-20-opioid-overdose-death-rate.aspx"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12699"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2022.2060428"},{"key":"e_1_3_3_34_2","unstructured":"SAMHSA. Buprenorphine Practitioner Locator. 2024. Accessed October 16 2023. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/find-treatment\/treatment-practitioner-locator?field_bup_state_value=45"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111290"},{"key":"e_1_3_3_36_2","unstructured":"Countering the Opioid Crisis: Time to Act Podcast. Stigma Addiction and Health Care. Accessed November 13 2023. https:\/\/nam.edu\/programs\/action-collaborative-on-countering-the-u-s-opioid-epidemic\/time-to-act-podcast\/"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2012.694599"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2017.12.022"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12328"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06257-4"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-021-00253-7"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11414-018-9629-4"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.13456"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000001851"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.15288\/jsad.2021.82.214"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.11.021"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.2839"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.1757"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-023-08165-9"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7006a4"},{"key":"e_1_3_3_51_2","unstructured":"Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl. Accessed February 6 2024. https:\/\/pcssnow.org\/courses\/practice-based-guidelines-buprenorphine-in-the-age-of-fentanyl-pcss-guidance\/"},{"issue":"10","key":"e_1_3_3_52_2","article-title":"Using telemedicine technology to assess physician outpatient teaching","volume":"47","author":"Biery N","year":"2015","unstructured":"Biery N, Bond W, Smith AB, LeClair M, Foster E. Using telemedicine technology to assess physician outpatient teaching. Fam Med. 2015;47(10):807-10.","journal-title":"Fam Med"},{"key":"e_1_3_3_53_2","unstructured":"Report to Congress: Utilization Management of Medication-Assisted Treatment in Medicaid. Medicaid and CHIP Payment and Access Commission (MACPAC). 2019. Accessed May 28 2024. https:\/\/www.macpac.gov\/publication\/report-to-congress-utilization-management-of-medication-assisted-treatment-in-medicaid\/"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109089"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.10.002"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3457"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.3544"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.13818"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342241303583","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342241303583","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342241303583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:50:42Z","timestamp":1777600242000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342241303583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,15]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/29767342241303583"],"URL":"https:\/\/doi.org\/10.1177\/29767342241303583","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,15]]}}}